Nestlé Health Science and Italy-based IdB Holding S.p.A. have signed a licensing agreement to develop and commercialize VOWST (fecal microbiota spores, live–brpk) across European markets, the companies announced May 28. The deal is contingent on regulatory clearance from the European Medicines Agency and positions the biologic as a potential first-line recurrence-prevention option for Clostridioides difficile infection on the continent.
VOWST is a prescription live biotherapeutic approved in the United States for preventing recurrence of C. difficile infection (rCDI) in adults following antibiotic treatment. The European licensing structure assigns IdB Holding — a Milan-headquartered producer of high-potency active pharmaceutical ingredients serving both pharmaceutical and health-food channels — commercialization rights in the region. Financial terms of the agreement were not disclosed, including royalty rate structure or milestone payments.
The move reflects a broader push by Nestlé Health Science to expand its gut-health and medical-nutrition footprint through asset-light partnership arrangements rather than direct market build-outs. rCDI carries significant clinical and economic burden in institutional foodservice and healthcare settings, where hospital-acquired infection rates shape procurement and formulary decisions across dietitian-led nutrition programs. Facilities managing high patient throughput — including long-term care and acute-care operators — have elevated exposure to rCDI, making microbiome therapeutics a growing adjacency to clinical nutrition protocols tracked closely by foodservice directors at integrated health systems.
For Food & Beverage Magazine network readers operating in the healthcare foodservice segment, the agreement underscores accelerating investment in the intersection of clinical nutrition and microbiome science. As health systems tighten supply chain oversight and prioritize evidence-based therapeutic nutrition, licensing structures like the Nestlé–IdB deal signal how large nutrition companies are deploying partnership models to reach regulated European markets without committing to full infrastructure overhead. The EMA review timeline was not specified in the announcement.
IdB Holding's existing manufacturing infrastructure in high-potency ingredient production gives the partnership a built-in scale advantage should EMA approval proceed. Nestlé Health Science retains originator rights to VOWST globally, preserving its position in the U.S. market while extending potential revenue streams through the European licensing arrangement. Operators in the healthcare foodservice and medical nutrition segments will want to monitor EMA proceedings as they evaluate formulary and dietary protocol planning over the next 12 to 24 months.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
